Pharma News
13 Apr 2025 to 19 Apr 2025
Apr 18, 2025
New trial shows weight-loss pill is as effective as Ozempic - The Age
Eli Lilly's experimental pill, orforglipron, demonstrated comparable effectiveness to the blockbuster drug Ozempic in reducing weight and blood sugar among Type 2 diabetes patients in a phase 3 trial. Participants lost about 7 kg over 40 weeks, with further weight loss anticipated. Lilly plans to seek global regulatory approvals for orforglipron this year.
Apr 18, 2025
FDA Approves Sanofi-Regeneron's Dupixent for Dermatological Condition - TradingView
The FDA has approved Sanofi and Regeneron's Dupixent for patients aged 12 and older with chronic spontaneous urticaria (CSU), following a previous rejection in 2023. The companies anticipate over 300,000 eligible patients in the U.S. Dupixent, which generated approximately €13 billion in sales last year, is also used for asthma, eczema, and other immune-related conditions.
Apr 18, 2025
A Pharmacist's Overview of Major Patent Expirations: Looking Ahead to 2025 and Later
This year marks a significant shift in the pharmaceutical industry as several blockbuster drugs, including Ticagrelor (Brilinta; AstraZeneca), Sacubitril/Valsartan (Entresto; Novartis), and Rivaroxaban (Xarelto; Bayer), are set to lose patent protection, paving the way for generics and biosimilars. Pharmacists must prepare for changes in inventory and patient counseling as competition increases.
Apr 18, 2025
Eli Lilly's recently developed GLP-1 weight loss medication, available in pill format, is expected to be less expensive than Ozempic.
Eli Lilly's experimental oral GLP-1 drug, orforglipron, has shown promising results in a Phase 3 trial, helping type 2 diabetes patients lose 16 pounds, comparable to Novo Nordisk's Ozempic. The pill, which does not require refrigeration, aims to provide a more accessible weight loss option. Lilly plans to seek regulatory approvals by year-end.
Apr 18, 2025
A new weight loss medication may serve as a practical substitute for Ozempic and Mounjaro: Here's the reasoning behind it.
Eli Lilly's experimental oral weight-loss drug, orforglipron, has shown promising results in Phase 3 trials, matching the efficacy of Ozempic in lowering weight and blood sugar. The once-daily pill, which can be taken without dietary restrictions, could revolutionize the GLP-1 drug market. Lilly plans to seek regulatory approval by year-end, with further data expected in 2026.
Apr 18, 2025
SA Inquires: Which weight-loss pharmaceutical stock is currently the top choice? - LongPort
Shares of obesity drug developers fluctuated this week following positive news for Eli Lilly's orforglipron and negative updates for Pfizer's danuglipron. Novo Nordisk's Wegovy continues to hold a strong position in the market, with potential new oral semaglutide options on the horizon. Analysts suggest that despite challenges, Novo Nordisk remains a strong contender in the obesity treatment landscape.
Apr 18, 2025
Geropharm has obtained approval for a generic version of Eli Lilly's Munjaro - GxP News
Russia's Geropharm has launched Sejaro (tirzepatide), a generic anti-obesity drug bioequivalent to Eli Lilly's Munjaro, set to enter the market in May at a lower cost. Sejaro, an injection pen, targets abdominal obesity and has shown significant weight loss in trials. Geropharm previously introduced Ozempic and Vegovi, and is also conducting trials for GP40331 (semaglutide).
Apr 17, 2025
In a recent trial, Eli Lilly's weight-loss medication orforglipron has shown effectiveness comparable to that of Ozempic - Brisbane Times.
Eli Lilly's experimental pill, orforglipron, demonstrated comparable effectiveness to the popular drug Ozempic in reducing weight and blood sugar among Type 2 diabetes patients in a phase 3 trial. Participants lost about 7 kg over 40 weeks, with further weight loss potential. Lilly plans to seek global regulatory approvals for orforglipron this year.
Apr 17, 2025
Eli Lilly's oral medication for weight loss demonstrates potential during upheaval in the pharmaceutical industry - The Express Tribune
Eli Lilly has announced promising early results from clinical trials of its oral drug orforglipron, a GLP-1 treatment for diabetes and weight loss. The drug showed effectiveness in lowering blood sugar and aiding weight loss without serious side effects. If approved by the FDA, orforglipron could be the first oral GLP-1 drug for weight loss, expanding access to obesity treatments.
Apr 17, 2025
Daily Medication Could Be as Effective as Ozempic for Weight Management and Blood Sugar Control
Eli Lilly announced that its daily pill, orforglipron, may effectively lower blood sugar and aid weight loss in Type 2 diabetes patients, comparable to injectable drugs Mounjaro and Ozempic. The company plans to seek FDA approval for obesity later this year and for diabetes in 2026, with expectations of it becoming a major blockbuster.
Apr 17, 2025
Lilly announces that a daily medication may help reduce blood sugar levels and weight in individuals with Type 2 diabetes.
Eli Lilly announced that its experimental oral pill, orforglipron, effectively lowered blood sugar and induced weight loss in Type 2 diabetes patients. In a phase 3 trial, it reduced A1C levels by 1.6% and participants lost up to 16 pounds. If approved, orforglipron would be the second oral GLP-1 drug in the U.S., following Novo Nordisk's Rybelsus.
Apr 17, 2025
FDA Orders Manufacturers of Imitation Weight Loss Medications to Cease Activities - KFF Health News
The FDA has ordered the cessation of operations for producers of copycat weight-loss drugs, impacting access to cheaper alternatives for patients as shortages of blockbuster drugs like Wegovy and Zepbound have ended. Eli Lilly's new daily pill, orforglipron, shows promise as an effective weight-loss treatment, potentially transforming patient care if approved.
Apr 17, 2025
Novo Nordisk will restart the distribution of its growth hormone Norditropin in South Korea - KBR
Novo Nordisk Pharma Korea announced the resumption of Norditropin Prefilled Pen (somatropin) supply, which had been out of stock since late 2022 due to domestic shortages. The announcement was made at a pediatric endocrinology symposium in Seoul, highlighting the importance of growth hormone therapy for children with various growth disorders.
Apr 17, 2025
AstraZeneca Allegedly Hinders Competition from Biosimilars for Medication Treating Rare Diseases
A proposed class action lawsuit has been filed against Alexion Pharmaceuticals, a division of AstraZeneca, alleging unlawful monopoly practices regarding the blood-disorder drug Soliris. EmblemHealth claims Alexion manipulated patents to delay biosimilar competition, potentially costing over $2 billion. The lawsuit argues this violates U.S. antitrust laws, as Soliris can cost up to $500,000 annually per patient.
Apr 17, 2025
Study reveals Eli Lilly's weight-loss medication is as effective as Ozempic, leading to a spike in stock prices.
Eli Lilly's experimental pill, orforglipron, demonstrated comparable efficacy to Ozempic in reducing weight and blood sugar in Type 2 diabetes patients, prompting a 13.3% surge in shares. The company plans to seek regulatory approvals by year-end. The trial showed patients lost an average of 16 pounds, with a favorable safety profile. Lilly aims to lead the market for oral weight-loss treatments.
Apr 17, 2025
A woman from the Adams Center and 30 others found guilty for their involvement in drug trafficking operations - WWNY
An Adams Center woman, Terrah Frederick, and 30 others were convicted in a major drug trafficking operation in New York, distributing fentanyl, heroin, methamphetamine, and cocaine. Frederick received a four-year sentence, while Devine Mobley of Syracuse was sentenced to three and a half years. The investigation, dubbed “Operation Blockbuster,” led to significant drug seizures valued over $500,000.
Apr 17, 2025
Eli Lilly reports that its GLP-1 oral medication for diabetes and weight management has shown effectiveness in a study and intends to pursue FDA approval.
Eli Lilly and Co. announced successful Phase 3 trial results for orforglipron, a once-daily oral GLP-1 medication for Type 2 diabetes. The trial showed an average A1C reduction of 1.3% to 1.6% and an average weight loss of 16 pounds. Eli Lilly plans to submit the drug for FDA approval in 2026 and for global regulatory approval by year-end.
Apr 17, 2025
Lilly's Weight-Loss Medication Proves Comparable to Ozempic, Stock Prices Rise - GV Wire
Eli Lilly's experimental pill, orforglipron, demonstrated weight loss and blood sugar reduction comparable to the blockbuster drug Ozempic in diabetes patients. The company plans to seek regulatory approvals by year-end. Shares surged 13.3% following the trial results, which showed patients lost an average of 16 pounds. Lilly aims to lead the market for oral weight-loss treatments.
Apr 17, 2025
The Potential Impact of a New Weight-Loss Medication on Health | TIME
David Ricks, CEO of Eli Lilly, expressed caution as the company prepares for a critical meeting regarding a new drug's testing phase. Despite promising early studies, Ricks acknowledged the uncertainty inherent in testing on larger populations, reflecting on his experience with both successful and failed drug developments at the Indianapolis-based pharmaceutical giant.
Apr 17, 2025
NewAmsterdam Pharma Names Adele Gulfo as a Member of its Board of Directors - Stock Titan
NewAmsterdam Pharma has appointed Adele Gulfo to its Board of Directors. Gulfo, a seasoned pharmaceutical leader with experience in launching blockbuster drugs like LIPITOR® and CRESTOR®, will aid in the company's strategy as it prepares for the potential launch of obicetrapib, an oral LDL-C lowering therapy for cardiovascular disease patients.
Apr 17, 2025
GSK receives UK authorization for blood cancer treatment - The Times
GSK's blood cancer drug, Blenrep, has received approval from the UK's Medicines and Healthcare Products Regulatory Agency for treating adults with multiple myeloma. This marks the first global approval for Blenrep, which is expected to generate peak sales of over £3 billion. GSK anticipates five significant regulatory approvals this year and aims to launch 14 pipeline assets by 2031.
